Plain-English translation of NCT06246916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing combined with , two experimental medications designed to help your immune system fight melanoma. Researchers want to compare how well and safely this new combination works compared to an already-approved medication combination called Opdualag, which contains relatlimab and nivolumab. The study will help doctors understand whether the new treatment might be better for patients like you.
Melanoma is a serious form of skin cancer, and while some patients benefit from existing immunotherapy treatments, doctors are always looking for better options that might work more effectively with fewer side effects. This trial will help determine if the new medication combination could offer improved results for people with advanced melanoma.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication combination or the approved medication combination. You will receive your assigned treatment and have regular visits with the research team to monitor how well it's working, check for side effects, and have blood tests and scans. The trial will also track how much medication is in your bloodstream and whether your body develops antibodies against the treatment.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States